- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05536141
Et fase 1-studie af AB521 i nyrecellekarcinom og andre faste tumorer (ARC-20)
En fase 1, åben-label, dosiseskalering og dosisudvidelsesundersøgelse, for at undersøge sikkerheden, tolerabiliteten og farmakokinetisk profil af AB521 monoterapi hos deltagere med klarcellet nyrecellekarcinom og andre faste tumorer
The purpose of this study is to evaluate the safety and tolerability of:
- casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and
- casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab or zimberelimab and ipilimumab or tivozanib or ivonescimab or zimberelimab and axitinib in participants with ccRCC in the dose expansion stage.
Studieoversigt
Status
Betingelser
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Medical Director
- Telefonnummer: +1-510-462-3330
- E-mail: ClinicalTrialInquiry@arcusbio.com
Studiesteder
-
-
-
Camperdown, Australien
- Ikke rekrutterer endnu
- Research Site
-
Melbourne, Australien
- Rekruttering
- Research Site
-
Sydney, Australien
- Rekruttering
- Research Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35294
- Rekruttering
- Research Site
-
-
California
-
San Diego, California, Forenede Stater, 92093
- Rekruttering
- Research Site
-
Santa Monica, California, Forenede Stater, 90404
- Rekruttering
- Research Site
-
-
Florida
-
Miami, Florida, Forenede Stater, 33136
- Rekruttering
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322-1013
- Rekruttering
- Research Site
-
-
Kentucky
-
Louisville, Kentucky, Forenede Stater, 40202
- Rekruttering
- Research Site
-
-
Louisiana
-
New Orleans, Louisiana, Forenede Stater, 70121
- Rekruttering
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21287
- Rekruttering
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215
- Rekruttering
- Research Site
-
-
Michigan
-
Detroit, Michigan, Forenede Stater, 48202
- Rekruttering
- Research Site
-
Detroit, Michigan, Forenede Stater, 48201
- Rekruttering
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68124
- Rekruttering
- Research Site
-
-
New York
-
New York, New York, Forenede Stater, 10065
- Rekruttering
- Research Site
-
New York, New York, Forenede Stater, 10029
- Rekruttering
- Research Site
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44106
- Rekruttering
- Research Site
-
Cleveland, Ohio, Forenede Stater, 44195
- Rekruttering
- Research Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15232
- Rekruttering
- Research Site
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37203
- Rekruttering
- Research Site
-
Nashville, Tennessee, Forenede Stater, 37240
- Rekruttering
- Research Site
-
-
Texas
-
San Antonio, Texas, Forenede Stater, 78229
- Rekruttering
- Research Site
-
-
-
-
-
Barcelona, Spanien
- Rekruttering
- Research Site
-
-
-
-
-
Seoul, Sydkorea
- Rekruttering
- Research Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
-
Must have at least one measurable lesion per RECIST guidance
-
Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 1
-
Disease-specific criteria for dose escalation:
- Participants may have any pathologically confirmed solid tumor type where no other treatment options are available
- Creatinine clearance ≥ 40 mL/min
Disease-specific criteria for dose-expansion:
- Histologically confirmed ccRCC
- Creatinine clearance ≥ 40 mL/min
Key Exclusion Criteria:
- Use of any live vaccines against infectious diseases (eg, influenza, varicella) within 4 weeks (28 days) of initiation of investigational product
- Has any other clinically significant cardiac, respiratory, or other medical or psychiatric condition that might interfere with a participant's participation in the clinical study or make the administration of investigational product hazardous
- History of trauma or major surgery within 28 days prior to the first dose of investigational product
- For all expansion cohorts: prior treatment with an hypoxia inducible factor (HIF)-2α inhibitor (except for the tivozanib +/- casdatifan cohort). For the casdatifan + cabozantinib combination cohort, any prior treatment with cabozantinib. For casdatifan + zimberelimab and casdatifan + zimberelimab + ipilimumab cohorts, any prior systemic treatment when cancer is present.
- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Dose Escalation Cohort 1
Participants will receive casdatifan orally once daily |
Administered as specified in the treatment arm
Andre navne:
|
|
Eksperimentel: Dose Escalation Cohort 2
Participants will receive casdatifan orally once daily |
Administered as specified in the treatment arm
Andre navne:
|
|
Eksperimentel: Dose Escalation Cohort 3
Participants will receive casdatifan orally twice daily |
Administered as specified in the treatment arm
Andre navne:
|
|
Eksperimentel: Dose Escalation Cohort 4
Participants will receive casdatifan orally once daily |
Administered as specified in the treatment arm
Andre navne:
|
|
Eksperimentel: Dose Escalation Cohort 5
Participants will receive casdatifan orally once daily |
Administered as specified in the treatment arm
Andre navne:
|
|
Eksperimentel: Dose Expansion Cohort 1
Participants will receive casdatifan orally |
Administered as specified in the treatment arm
Andre navne:
|
|
Eksperimentel: Dose Expansion Cohort 2
Participants will receive casdatifan orally |
Administered as specified in the treatment arm
Andre navne:
|
|
Eksperimentel: Dose Expansion Cohort 3
Participants will receive casdatifan orally |
Administered as specified in the treatment arm
Andre navne:
|
|
Eksperimentel: Dose Expansion Cohort 4
Participants will receive casdatifan orally with with cabozantinib orally |
Administered as specified in the treatment arm Administered as specified in the treatment arm
Andre navne:
|
|
Eksperimentel: Dose Expansion Cohort 5
Participants will receive casdatifan orally |
Administered as specified in the treatment arm
Andre navne:
|
|
Eksperimentel: Dose Expansion Cohort 6
Participants will receive casdatifan orally |
Administered as specified in the treatment arm
Andre navne:
|
|
Eksperimentel: Dose Expansion Cohort 7
Participants will receive casdatifan orally with zimberelimab infusion |
Administered as specified in the treatment arm
Andre navne:
Administered as specified in the treatment arm
Andre navne:
|
|
Eksperimentel: Dose Expansion Cohort 8
Participants will receive casdatifan orally |
Administered as specified in the treatment arm
Andre navne:
|
|
Eksperimentel: Dose Expansion Cohort 9
Participants will receive casdatifan orally with zimberelimab infusion and ipilimumab infusion |
Administered as specified in the treatment arm
Andre navne:
Administered as specified in the treatment arm Administered as specified in the treatment arm
Andre navne:
|
|
Eksperimentel: Dose Expansion Cohort 10
Participants will receive casdatifan orally with zimberelimab infusion and ipilimumab infusion |
Administered as specified in the treatment arm
Andre navne:
Administered as specified in the treatment arm Administered as specified in the treatment arm
Andre navne:
|
|
Eksperimentel: Dose Expansion Cohort 11
Participants will receive casdatifan orally with tivozanib orally or tivozanib orally only. |
Administered as specified in the treatment arm
Andre navne:
Administered as specified in the treatment arm |
|
Eksperimentel: Dose Expansion Cohort 12
Participants will receive casdatifan orally with ivonescimab infusion. |
Administered as specified in the treatment arm
Andre navne:
Administered as specified in the treatment arm |
|
Eksperimentel: Dose Expansion Cohort 13
Participants will receive casdatifan orally with zimberelimab infusion and axitinib orally. |
Administered as specified in the treatment arm
Andre navne:
Administered as specified in the treatment arm
Andre navne:
Administered as specified in the treatment arm |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Antal deltagere med dosisbegrænsende toksicitet (DLT'er)
Tidsramme: Op til 4 måneder
|
Op til 4 måneder
|
|
Antal deltagere med uønskede hændelser (AE'er)
Tidsramme: Op til 4 måneder
|
Op til 4 måneder
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Objektiv responsrate målt ved responsevalueringskriterier i solide tumorer (RECIST) v1.1
Tidsramme: Op til 4 måneder
|
Op til 4 måneder
|
|
Plasmakoncentration af casdatifan
Tidsramme: Op til 4 måneder
|
Op til 4 måneder
|
|
Areal under plasmakoncentrationstidskurven (AUC) for casdatifan
Tidsramme: Op til 4 måneder
|
Op til 4 måneder
|
|
Maksimal observeret plasmakoncentration (Cmax) af casdatifan
Tidsramme: Op til 4 måneder
|
Op til 4 måneder
|
|
Duration of Response as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Tidsramme: Up to 4 months
|
Up to 4 months
|
|
Progression-free survival as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Tidsramme: Up to 4 months
|
Up to 4 months
|
|
Overall survival
Tidsramme: Up to 4 months
|
Up to 4 months
|
|
Area under the plasma concentration time curve (AUC) of casdatifan in combination with tivozanib
Tidsramme: Up to 4 months
|
Up to 4 months
|
|
Maximum Observed Plasma Concentration (Cmax) of casdatifan in combination with tivozanib
Tidsramme: Up to 4 months
|
Up to 4 months
|
|
Area under the plasma concentration time curve (AUC) of casdatifan in combination with ivonescimab
Tidsramme: Up to 4 months
|
Up to 4 months
|
|
Maximum Observed Plasma Concentration (Cmax) of casdatifan in combination with ivonescimab
Tidsramme: Up to 4 months
|
Up to 4 months
|
|
Percentage of patients who are ADA-positive and ADA-negative against ivonescimab
Tidsramme: Up to 4 months
|
Up to 4 months
|
|
Area under the plasma concentration time curve (AUC) of casdatifan in combination with zimberelimab and axitinib
Tidsramme: Up to 4 months
|
Up to 4 months
|
|
Maximum Observed Plasma Concentration (Cmax) of casdatifan in combination with zimberelimab and axitinib
Tidsramme: Up to 4 months
|
Up to 4 months
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Medical Director, Arcus Biosciences
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Mandlige urogenitale sygdomme
- Nyresygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Neoplasmer efter histologisk type
- Neoplasmer, kirtel og epitel
- Adenocarcinom
- Urologiske neoplasmer
- Karcinom
- Karcinom, nyrecelle
- Nyre-neoplasmer
- Erythrocytosis, familiær, 4
- Aminosyrer, peptider og proteiner
- Proteiner
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Azoler
- Kulbrinter
- Kulbrinter, cyklisk
- Carboxylsyrer
- Kulbrinter, aromatisk
- Amider
- Antistoffer, monoklonal, humaniseret
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Benzenderivater
- Syrer, carbocykliske
- Benzoates
- Benzamider
- Indazoles
- Pyrazoler
- Axitinib
- Ipilimumab
- Zimberelimab
- Cabozantinib
- tivozanib
Andre undersøgelses-id-numre
- ARC-20
- 2024-519142-70-00 (Ctis)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Arcus will provide access to individual de-identified participant data and related study documents [e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)] upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
For more information, please visit our website.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .